Literature DB >> 8410049

Contrasting effects of immunosuppression on herpes simplex virus type I (HSV I) induced central nervous system (CNS) demyelination in mice.

L F Kastrukoff1, A S Lau, G Y Leung, E E Thomas.   

Abstract

We previously reported that lip inoculation of Herpes simplex virus type I (HSV I) in specific strains of mice would induce multifocal brain demyelination (MBD). The mechanisms mediating the development of MBD are unknown. In this study, five inbred strains of mice (C57BL/6J, Balb/cByJ, A/J, SJL/J, PL/J) immunosuppressed with either irradiation (IR), cyclophosphamide (CY), or cyclosporin A (CP) along with three immune deficient strains (C57BL/6J nu/nu, Balb/cByJ nu/nu, C57BL/6J bg/bg) were lip inoculated with HSV I to determine the effect of immunosuppression on viral spread throughout the brain and the development of demyelination during the acute stage of infection. Mortality increased in all groups when compared with controls but was greatest in A/J, SJL/J, and PL/J strains, where all mice died before day 6 PI. In contrast with immunocompetent C57BL/6J mice where virus is restricted to the brainstem, virus spread throughout the brain of immunosuppressed C57BL/6J, C57BL/6J nu/nu, and C57BL/6J bg/bg mice. Despite viral spread throughout the brain of immunosuppressed C57BL/6J, C57BL/6J nu/nu, Balb/cByJ and Balb/cByJ nu/nu mice, MBD did not develop. MBD did develop however, in both HSV I infected C57BL/6J bg/bg and CP treated Balb/cByJ mice. Immunosuppression of HSV I infected Balb/cByJ mice prevents the development of demyelination at the trigeminal root entry zone (TREZ) of the brainstem while in Balb/cByJ nu/nu mice, the extent of demyelination at TREZ was reduced and delayed when compared with immunocompetent controls. These results suggest that the immune system plays an important role in limiting viral spread in the brain as well as in the development of demyelination at TREZ and of MBD throughout the brain during the acute phase of infection. Virus alone does not induce MBD in this animal model of virus induced CNS demyelination but is a prerequisite for its development.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410049      PMCID: PMC7172415          DOI: 10.1016/0022-510x(93)90167-w

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  32 in total

1.  Morphology of central nervous system disease in immunosuppressed mice after peripheral herpes simplex virus inoculation. Trigeminal root entry zone.

Authors:  J J Townsend; J R Baringer
Journal:  Lab Invest       Date:  1979-02       Impact factor: 5.662

Review 2.  Cyclosporine.

Authors:  B D Kahan
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

3.  Multifocal CNS demyelination following peripheral inoculation with herpes simplex virus type 1.

Authors:  L F Kastrukoff; A S Lau; S U Kim
Journal:  Ann Neurol       Date:  1987-07       Impact factor: 10.422

4.  Pathogenesis of demyelination induced by a mouse hepatitis.

Authors:  L P Weiner
Journal:  Arch Neurol       Date:  1973-05

Review 5.  Influence of cyclosporine on CTL behavior in vitro and in vivo.

Authors:  C G Orosz; N E Zinn; P W Adams; M B Widmer; R M Ferguson
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

6.  Herpes simplex virus type I (HSV I)-induced multifocal central nervous system (CNS) demyelination in mice.

Authors:  L F Kastrukoff; A S Lau; G Y Leung; D G Walker; E E Thomas; D Walker
Journal:  J Neuropathol Exp Neurol       Date:  1992-07       Impact factor: 3.685

7.  The demyelinating effect of corneal HSV infections in normal and nude (athymic) mice.

Authors:  J J Townsend
Journal:  J Neurol Sci       Date:  1981-06       Impact factor: 3.181

8.  Central nervous system infection and immune response in mice inoculated into the lip with herpes simplex virus type 1.

Authors:  L Kastrukoff; T Hamada; U Schumacher; C Long; P C Doherty; H Koprowski
Journal:  J Neuroimmunol       Date:  1982-06       Impact factor: 3.478

9.  Herpetic stromal keratitis-evidence for cell-mediated immunopathogenesis.

Authors:  J F Metcalf; H E Kaufman
Journal:  Am J Ophthalmol       Date:  1976-12       Impact factor: 5.258

10.  Effect of cyclosporin A on human lymphocyte responses in vitro. IV. Production of T cell stimulatory growth factors and development of responsiveness to these growth factors in CsA-treated primary MLR cultures.

Authors:  A D Hess; P J Tutschka; Z Pu; G W Santos
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

View more
  6 in total

1.  Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.

Authors:  K-W Peng; R Myers; A Greenslade; E Mader; S Greiner; M J Federspiel; A Dispenzieri; S J Russell
Journal:  Gene Ther       Date:  2012-04-05       Impact factor: 5.250

Review 2.  Immune response of T cells during herpes simplex virus type 1 (HSV-1) infection.

Authors:  Jie Zhang; Huan Liu; Bin Wei
Journal:  J Zhejiang Univ Sci B       Date:  2017 Apr.       Impact factor: 3.066

3.  Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

Authors:  Mark A Currier; Rebecca A Gillespie; Nancy M Sawtell; Yonatan Y Mahller; Greg Stroup; Margaret H Collins; Hirokazu Kambara; E Antonio Chiocca; Timothy P Cripe
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

4.  Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice.

Authors:  J Peltoniemi; E K Broberg; A Halenius; N Setala; J-P Eralinna; A A Salmi; M Roytta; V Hukkanen
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

5.  The effect of mouse strain on herpes simplex virus type 1 (HSV-1) infection of the central nervous system (CNS).

Authors:  Lorne F Kastrukoff; Allen S Lau; Eva E Thomas
Journal:  Herpesviridae       Date:  2012-03-26

Review 6.  Herpesviruses--a rationale for antiviral treatment in multiple sclerosis.

Authors:  T Bergström
Journal:  Antiviral Res       Date:  1999-02       Impact factor: 5.970

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.